[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
June 25, 2003

Use of Biologics for Rheumatoid Arthritis Tempered by Concerns Over Safety, Cost

JAMA. 2003;289(24):3229-3230. doi:10.1001/jama.289.24.3229

In the few short years since biologic agents were introduced for treating rheumatoid arthritis, the drugs have sparked interest among clinicians and patients because of their purported superiority to standard therapies in delaying or preventing the deformity and disability associated with this condition. But not everyone is convinced that the availability of these agents in the treatment of this chronic and often debilitating disease is an unmixed blessing.

While initial studies demonstrated that patients with rheumatoid arthritis who took biologic agents had decreased symptoms compared with those receiving standard therapy, safety of the drugs remains a concern, along with cost .

First Page Preview View Large
First page PDF preview
First page PDF preview